Noxopharm Ltd has released a press release.
Data Shows Idronoxil Holds Key to Problem of COLD Cancers
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- COVID-19 Trial Program to Commence in Europe
- Pro-rata Non-Renounceable Rights Issue Fully Allocated
- ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer
- FDA allows Veyonda Pre-IND Submission for COVID-19
- Entitlement Offer Prospectus
Later from Noxopharm
- Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’ Tumors to ‘Hot’
- Noxopharm 2020 June quarter Appendix 4C & Activities Report
- Peer-Reviewed Publication Strengthens Case For Veyonda
- Appendix 4E and Audited Financial Statements FY2020
- Veyonda COVID-19 Study Approved For Immediate Start
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm